Clinical Significance of Survivin Expression in Patients with Urothelial Carcinoma

Background. Survivin is a member of the inhibitors of apoptosis protein family that plays an important role in carcinogenesis. Here, we examined the association between survivin expression and clinical outcome in urothelial carcinoma of the bladder (UCB). Methods. A total of 56 histopathologically confirmed UCB patients were recruited from the Department of Urology of Chiayi Christian Hospital from August 2007 to May 2009. Immunohistochemistry (IHC) was used to detect the survivin expression in tumor tissues. The –31 C/G polymorphism in survivin promoter region was determined by polymerase chain reaction-restricted fragment length polymorphism. Results. The frequency of high survivin expression was significantly higher in muscle-invasive tumors (66.6%) than in non-muscle-invasive tumors (34.2%) (P = 0.042) and in poorly differentiated (85.7%) tumors than in moderately differentiated tumors (30.8%) (P = 0.0014). The higher frequency of risk genotypes (C/C and C/G) was found in the median (72.7%) and high (68.0%) survivin expression groups. The multivariate analysis showed that a high survivin expression level was a potential predictive biomarker of poor overall survival (P = 0.02). Conclusion. Our results suggest that the high survivin expression was associated with tumor stage and grade and may present a predictive marker of overall survival in UCB.

[1]  Aaas News,et al.  Book Reviews , 1893, Buffalo Medical and Surgical Journal.

[2]  Hong-yan Cheng,et al.  Association between survivin -31G>C polymorphism and cancer risk: meta-analysis of 29 studies , 2014, Journal of Cancer Research and Clinical Oncology.

[3]  C. Kwak,et al.  Prognostic Role of Survivin in Bladder Cancer: A Systematic Review and Meta-Analysis , 2013, PloS one.

[4]  Zhi-hui Yang,et al.  Polymorphisms of survivin and its protein expression are associated with colorectal cancer susceptibility in Chinese population. , 2013, DNA and cell biology.

[5]  P. Singh,et al.  Diagnostic role of survivin in urinary bladder cancer. , 2013, Asian Pacific journal of cancer prevention : APJCP.

[6]  Cheng-ling Zhao,et al.  Expression of survivin and patients survival in non-small cell lung cancer: a meta-analysis of the published studies , 2012, Molecular Biology Reports.

[7]  S. Fulda,et al.  Survivin as a prognostic/predictive marker and molecular target in cancer therapy. , 2012, Current medicinal chemistry.

[8]  Yongmei Yin,et al.  Association between survivin −31G>C promoter polymorphism and cancer risk: a meta-analysis , 2012, European Journal of Human Genetics.

[9]  W. Marsden.  I and J , 2012 .

[10]  N. Sato,et al.  Nuclear, but not cytoplasmic, localization of survivin as a negative prognostic factor for survival in upper urinary tract urothelial carcinoma , 2012, Virchows Archiv.

[11]  B. Mittal,et al.  Survivin promoter −31G/C (rs9904341) polymorphism and cancer susceptibility: a meta-analysis , 2011, Molecular Biology Reports.

[12]  .. AsociaciónAmericanadeUrología.  [Non-muscle invasive bladder cancer]. , 2011, Archivos espanoles de urologia.

[13]  M. Ringnér,et al.  Prediction of Stage, Grade, and Survival in Bladder Cancer Using Genome-wide Expression Data: A Validation Study , 2010, Clinical Cancer Research.

[14]  H. Chiou,et al.  A significantly joint effect between arsenic and occupational exposures and risk genotypes/diplotypes of CYP2E1, GSTO1 and GSTO2 on risk of urothelial carcinoma. , 2009, Toxicology and applied pharmacology.

[15]  F. Montorsi,et al.  Survivin as a Prognostic Marker for Urothelial Carcinoma of the Bladder: A Multicenter External Validation Study , 2009, Clinical Cancer Research.

[16]  A. Chinnaiyan,et al.  Development of a multiplex quantitative PCR signature to predict progression in non-muscle-invasive bladder cancer. , 2009, Cancer research.

[17]  H. Chiou,et al.  Association between survivin gene promoter -31 C/G polymorphism and urothelial carcinoma risk in Taiwanese population. , 2009, Urology.

[18]  Y. Sekine,et al.  Gene expression of survivin and its spliced isoforms associated with proliferation and aggressive phenotypes of prostate cancer. , 2008, Urology.

[19]  Wun-Jae Kim,et al.  Molecular biomarkers in urothelial bladder cancer , 2008, Cancer science.

[20]  Anirban P. Mitra,et al.  Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history. , 2008, Reviews in urology.

[21]  Y. Lotan,et al.  Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder. , 2007, Urology.

[22]  N. K. Sah,et al.  Structural, functional and therapeutic biology of survivin. , 2006, Cancer letters.

[23]  T. Kakizoe.  Development and progression of urothelial carcinoma , 2006, Cancer science.

[24]  H. Zeng,et al.  Survivin nuclear labeling index: a superior biomarker in superficial urothelial carcinoma of human urinary bladder , 2006, Modern Pathology.

[25]  M. Akhtar,et al.  Survivin: Role in Diagnosis, Prognosis, and Treatment of Bladder Cancer , 2006, Advances in anatomic pathology.

[26]  K. Miller,et al.  Quantitative analysis of survivin mRNA expression in urine and tumor tissue of bladder cancer patients and its potential relevance for disease detection and prognosis , 2005, International journal of cancer.

[27]  J. Wei,et al.  Survivin protein expression positively correlated with proliferative activity of cancer cells in bladder cancer. , 2005, Indian journal of medical sciences.

[28]  C. Kwak,et al.  Expression of survivin, a novel inhibitor of apoptosis, in superficial transitional cell carcinoma of the bladder. , 2004, The Journal of urology.

[29]  Yong Xu,et al.  A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. , 2004, DNA and cell biology.

[30]  M. Mesri,et al.  Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  S. Chiou,et al.  Survivin - an anti-apoptosis protein: its biological roles and implications for cancer and beyond. , 2003, Medical science monitor : international medical journal of experimental and clinical research.

[32]  D. Altieri,et al.  Survivin in apoptosis control and cell cycle regulation in cancer. , 2003, Progress in cell cycle research.

[33]  G. Salvesen,et al.  Apoptosis: IAP proteins: blocking the road to death's door , 2002, Nature Reviews Molecular Cell Biology.

[34]  D. Altieri,et al.  A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma , 1997, Nature Medicine.

[35]  H. Tung,et al.  Progress in Cell Cycle Research , 1999, Progress in Cell Cycle Research.